Responses
Immune cell therapies and immune cell engineering
Original research
Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability
Compose a Response to This Article
Other responses
No responses have been published for this article.
